Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

BACKGROUND: Direct-acting antivirals (DAAs) are entering the hepatitis C virus (HCV) treatment landscape in Hong Kong, prompting the need for cost–effectiveness evaluations of these interventions to enable optimal use of healthcare resources. AIMS: This study aimed to compare the cost–effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuen, Man-Fung, Liu, Sze-Hang, Seto, Wai-Kay, Mak, Lung-Yi, Corman, Shelby L., Hsu, Danny C., Lee, Mary Y. K., Khan, Tsz K., Puenpatom, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990846/
https://www.ncbi.nlm.nih.gov/pubmed/32385703
http://dx.doi.org/10.1007/s10620-020-06281-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990846/
https://www.ncbi.nlm.nih.gov/pubmed/32385703
http://dx.doi.org/10.1007/s10620-020-06281-8

Ejemplares similares